.jpg)
Investigation of Immune Status for Assessment of a Mammary Gland Cancer Adjuvant Monotherapy Safety
Aim of investigation is a study of immune status at the tamoyfen antiestrogen and letrosol estrogen synthesis inhibitor use as an adjuvant monotherapy of a mammary gland cancer.
Materials and Methods. 26 patients with a mammary gland cancer of a stage T1-3H1-2M0, undergoing the adjuvant monotherapy with the tamoxyfen or letrosol preparations after a radical mastectomy, are included into investigation. A complex assessment of immune status was made prior to beginning of a hormonotherapy and in 4 months of treatment. The lymphocyte subpopulations were detected with a use of monoclonal antibodies, the immunoglobulins A, M, G — with a method of radial immunodiffusion.
Results. A tamoxyfen increases not only a general quantity of the T-lymphocytes, but a relative quantity of the T-lymphocytes-helpers, and also the T-lymphocytes-supressors, T-lymphocytes with receptors to interleukin-2 and a tumor necrosis factor, decreasing at the same time a number of NK-lymphocytes. An increase of the IgG concentration in a blood serum, and a decrease of the IgA and IgM concentration are registered at the background of tamoxyfen.
A letrosol stipulates a decrease of the T-lymphocyte general quantity, a relative quantity of the T-lymphocytes-supressors, NK-lymphocytes, T-lymphocytes with receptors to a tumor necrosis factor and T-lymphocytes-helpers, not altering a number of T-lymphocytes with receptors to interleukin-2. An increase of the IgM concentration and a decrease of the IgA and IgG content are also observed at a letrosol use.
Conclusion. A certain direction of revealed alterations is characteristic of each of investigated preparations, which testifies to necessity of the immunologic value dynamic control and a corresponding corrugated therapy.
